Asston Pharmaceu

How has been the historical performance of Asston Pharmaceu?

Asston Pharmaceu experienced significant growth from March 2024 to March 2025, with net sales rising to 25.04 Cr from 15.59 Cr, and profit after tax increasing to 4.33 Cr from 1.36 Cr. Key metrics such as EPS improved to 6.91 and operating profit margin rose to 24.64%, indicating a strengthening financial position.

Answer:<BR>The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28.10 Cr from 20.70 Cr. The book value per share adjusted increased to 17.6 from 11.45, reflecting the company's strengthening financial position.

Is Asston Pharmaceu overvalued or undervalued?

As of November 26, 2025, Asston Pharmaceu is considered overvalued with a PE ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35, despite outperforming the Sensex with a 1-week return of 17.65%.

As of 26 November 2025, Asston Pharmaceu's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a price-to-earnings (PE) ratio of 22.11, a price-to-book value of 2.20, and an EV to EBITDA ratio of 16.35. These metrics suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Asston Pharmaceu's PE ratio is lower than that of Sun Pharma (37.53) and Divi's Lab (69.71), both categorized as expensive, while it is slightly higher than Cipla (22.59) and Dr. Reddy's Labs (18.02), which are viewed as attractive. The company's recent stock performance has outpaced the Sensex, with a 1-week return of 17.65% compared to the Sensex's 0.50%, reinforcing the notion of overvaluation in the current market context.

When is the next results date for Asston Pharmaceuticals Ltd?

The next results date for Asston Pharmaceuticals Ltd is 29 May 2026.

The next results date for Asston Pharmaceuticals Ltd is scheduled for 29 May 2026.

Why is Asston Pharmaceuticals Ltd falling/rising?

As of 26-May, Asston Pharmaceuticals Ltd's stock price is at Rs 70.00, down 3.85%, and has significantly underperformed against the Sensex. The stock's persistent decline is attributed to stagnant trading activity and reduced investor participation.

As of 26-May, Asston Pharmaceuticals Ltd's stock price is falling, currently at Rs 70.00, reflecting a decrease of Rs 2.8 or 3.85%. The stock has underperformed significantly compared to the benchmark Sensex, which has gained 1.08% over the past week while Asston's stock has dropped by 3.67%. Over the past month, the stock has seen a decline of 13.58%, contrasting with a slight decrease of 0.85% in the Sensex.<BR><BR>Today's trading session has been particularly challenging for Asston Pharmaceuticals, as the stock opened with a loss of 3.85% and reached an intraday low of Rs 70. The stock has not shown any price range, remaining stagnant at this opening price throughout the day. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent downward trend.<BR><BR>Investor participation has also declined, with a delivery volume of only 1,000 shares on May 22, which is a significant drop of 61.54% compared to the 5-day average delivery volume. This lack of trading activity suggests reduced interest in the stock, contributing to its falling price. Overall, the combination of poor performance relative to the market, stagnant trading activity, and declining investor participation are key factors driving the stock's decline.

Which are the latest news on Asston Pharmaceu?